Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Dosage
3.2. Market Snippet by Age Group
3.3. Market Snippet by End-User
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Convenience of Patients
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Preference for Alternative Drug Delivery Modes
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Dosage
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Segment
7.3. Market Attractiveness Index, By Dosage Segment
7.3.1. 0.15mg Epinephrine Autoinjector*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. 0.3mg Epinephrine Autoinjector
7.3.3. 0.5mg Epinephrine Autoinjector
8. By Age Group
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group Segment
8.3. Market Attractiveness Index, By Age Group Segment
8.3.1. Under 6 Years Patients*
8.3.1.1. Introduction
8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.2. 6 to 12 Years Patients
8.3.3. Over 12 Years Patients
9. By End-User
9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.3. Market Attractiveness Index, By End-User Segment
9.3.1. Hospitals*
9.3.1.1. Introduction
9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3.2. Clinics
9.3.3. Individuals
10. By Region
10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.3. Market Attractiveness Index, By Region
10.4. North America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. U.S.
10.4.6.2. Canada
10.4.6.3. Mexico
10.5. Europe
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. Germany
10.5.6.2. U.K.
10.5.6.3. France
10.5.6.4. Italy
10.5.6.5. Spain
10.5.6.6. Rest of Europe
10.6. South America
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.6.6.1. Brazil
10.6.6.2. Argentina
10.6.6.3. Rest of South America
10.7. Asia Pacific
10.7.1. Introduction
10.7.2. Key Region-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age-Group
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.7.6.1. China
10.7.6.2. India
10.7.6.3. Japan
10.7.6.4. Australia
10.7.6.5. Rest of Asia Pacific
10.8. Middle East and Africa
10.8.1. Introduction
10.8.2. Key Region-Specific Dynamics
10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage
10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Mylan Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. ALK-Abello AS
12.3. Adamis Pharmaceuticals Corp.
12.4. Amneal Pharmaceuticals Inc.
12.5. Teva Pharmaceutical Industries Ltd.
12.6. Amedra Pharmaceuticals LLC
12.7. Sanofi Sa
12.8. Lincoln Medical Ltd
12.9. Antares Pharma Inc.
12.10. Novartis AG
12.11. Pfizer Inc.( Hospira Inc.) (List Not Exhaustive)
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us